BlackRock Investment Management’s Gyre Therapeutics GYRE Stock Holding History

BlackRock Investment Management’s Portfolio GYRE Stock Details GYRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-8	Closed	-$2K	–	4071
2016 Q1	$2K	Hold	8	–	–	﹤0.01%	3972
2015 Q4	$3K	Hold	8	–	–	﹤0.01%	3952
2015 Q3	$4K	Buy	8 +2	+33%	+$3.05K	﹤0.01%	3979
2015 Q2	$13K	Sell	6 -1	-14%	-$2K	﹤0.01%	3611
2015 Q1	$17K	Hold	7	–	–	﹤0.01%	3482
2014 Q4	$15K	Hold	7	–	–	﹤0.01%	3533
2014 Q3	$14K	Hold	7	–	–	﹤0.01%	3531
2014 Q2	$25K	Sell	7 -116	-94%	-$379K	﹤0.01%	3348
2014 Q1	$461K	Buy	123 +1	+0.8%	+$3.7K	﹤0.01%	2996
2013 Q4	$399K	Sell	122 -2	-2%	-$7.88K	﹤0.01%	3056
2013 Q3	$521K	Hold	124	–	–	﹤0.01%	2907
2013 Q2	$417K	Buy	+124	New	+$472K	﹤0.01%	2950

Other funds holding GYRE

EWM

Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

CCM

Colorado Capital Management Boulder, Colorado $293M AUM 22.17% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BlackRock Investment Management's GYRE Position: Q2 2016 in Review

BlackRock Investment Management sold out of Gyre Therapeutics (GYRE) in Q2 2016, closing a stake of 8 shares — an estimated $2K sold.

BlackRock Investment Management first reported a position in GYRE in Q2 2013 and held it in 12 quarters. The position peaked at $521K in Q3 2013. 31 funds tracked by Wall St. Rank hold GYRE as of Q2 2016.

BlackRock Investment Management reported no remaining Gyre Therapeutics position as of Q2 2016 after selling out during the quarter.
BlackRock Investment Management sold 8 Gyre Therapeutics shares in Q2 2016, an estimated $2K.
BlackRock Investment Management first reported a position in Gyre Therapeutics in Q2 2013 and held it in 12 quarters.
BlackRock Investment Management's Gyre Therapeutics position peaked at $521K in Q3 2013.
31 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q2 2016.

Based on BlackRock Investment Management's 13F filing for Q2 2016, filed 10 Aug 2016.